Home/Filings/4/0001209191-21-018435
4//SEC Filing

Reich Siegfried 4

Accession 0001209191-21-018435

CIK 0001595893other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 8:56 PM ET

Size

26.9 KB

Accession

0001209191-21-018435

Insider Transaction Report

Form 4
Period: 2021-03-04
Reich Siegfried
EVP & Chief Scientific Officer
Transactions
  • Sale

    Common Stock

    2021-03-04$103.65/sh6,220$644,70321,350 total
  • Sale

    Common Stock

    2021-03-04$105.71/sh3,103$328,01816,247 total
  • Sale

    Common Stock

    2021-03-04$107.85/sh3,679$396,7805,852 total
  • Sale

    Common Stock

    2021-03-04$110.59/sh700$77,4134,445 total
  • Exercise/Conversion

    Stock Option (right to buy)

    2021-03-0435,550114,450 total
    Exercise: $51.28Exp: 2030-03-01Common Stock (35,550 underlying)
  • Exercise/Conversion

    Common Stock

    2021-03-04$51.28/sh+35,550$1,823,00439,395 total
  • Sale

    Common Stock

    2021-03-04$102.01/sh3,005$306,54036,390 total
  • Sale

    Common Stock

    2021-03-04$102.87/sh8,820$907,31327,570 total
  • Sale

    Common Stock

    2021-03-04$104.97/sh2,000$209,94019,350 total
  • Sale

    Common Stock

    2021-03-04$107.13/sh6,716$719,4859,531 total
  • Sale

    Common Stock

    2021-03-04$108.92/sh707$77,0065,145 total
  • Sale

    Common Stock

    2021-03-04$111.46/sh600$66,8763,845 total
Footnotes (12)
  • [F1]Reported transaction occurred pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on November 23, 2020.
  • [F10]The weighted average sale price for the transaction reported was $110.59, and the range of prices were between $110.05 and $110.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F11]The weighted average sale price for the transaction reported was $111.46, and the range of prices were between $111.20 and $111.96. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F12]25% of the shares vested on March 2, 2021 and 1/48th of the shares vest monthly thereafter over the next three years.
  • [F2]The weighted average sale price for the transaction reported was $102.01, and the range of prices were between $101.37 and $102.32. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F3]The weighted average sale price for the transaction reported was $102.87, and the range of prices were between $102.38 and $103.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F4]The weighted average sale price for the transaction reported was $103.65, and the range of prices were between $103.40 and $104.20. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F5]The weighted average sale price for the transaction reported was $104.97, and the range of prices were between $104.46 and $105.46. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F6]The weighted average sale price for the transaction reported was $105.71, and the range of prices were between $105.47 and $106.36. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F7]The weighted average sale price for the transaction reported was $107.13, and the range of prices were between $106.53 and $107.53. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F8]The weighted average sale price for the transaction reported was $107.85, and the range of prices were between $107.54 and $108.42. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.
  • [F9]The weighted average sale price for the transaction reported was $108.92, and the range of prices were between $108.75 and $109.63. Upon request by the SEC staff, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price will be provided.

Issuer

Turning Point Therapeutics, Inc.

CIK 0001595893

Entity typeother

Related Parties

1
  • filerCIK 0001351888

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 8:56 PM ET
Size
26.9 KB